Chimerix: Tackling A Strong Unmet Need With Promising Data

onurdongel Topline Summary Chimerix, Inc (NASDAQ:CMRX) is a microcap biotech stock focused mainly on development of novel treatments for subsets of high-grade glioma, a form of brain cancer, as well as other therapies. While they have the same serious risks of pipeline failure that all developmental biotechs carry, the fact that they have double their market cap in assets and a 2+ year runway gives a lot of fuel for the investment thesis. For the conservative investor, I don't think there's enough here  ...